UBS Group Reaffirms “Neutral” Rating for Avantor (NYSE:AVTR)

Avantor (NYSE:AVTR)‘s stock had its “neutral” rating reiterated by research analysts at UBS Group in a research report issued on Friday, Marketbeat Ratings reports. They presently have a $25.00 price objective on the stock, down from their prior price objective of $29.00. UBS Group’s target price would indicate a potential upside of 12.91% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Wells Fargo & Company lowered their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price target on shares of Avantor in a report on Thursday, September 26th. Barclays cut their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Finally, Robert W. Baird decreased their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.38.

Avantor Stock Down 1.9 %

Shares of NYSE AVTR opened at $22.14 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The company has a market capitalization of $15.07 billion, a P/E ratio of 48.13, a P/E/G ratio of 3.42 and a beta of 1.28. The company has a 50 day simple moving average of $21.45 and a 200-day simple moving average of $23.35. Avantor has a 1 year low of $19.59 and a 1 year high of $28.00.

Institutional Trading of Avantor

Institutional investors and hedge funds have recently bought and sold shares of the business. MassMutual Private Wealth & Trust FSB boosted its position in shares of Avantor by 99.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock worth $26,000 after buying an additional 625 shares during the period. UMB Bank n.a. acquired a new stake in shares of Avantor during the third quarter worth approximately $49,000. Nisa Investment Advisors LLC increased its stake in shares of Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares during the last quarter. GAMMA Investing LLC boosted its stake in Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after acquiring an additional 1,285 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its holdings in Avantor by 278.0% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock worth $130,000 after acquiring an additional 3,700 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.